Get Permission Yadav: Understanding the complexities of post-tuberculosis lung disease: Implications for global health


Editorial

Tuberculosis continues to be a major global health concern, affecting millions of individuals worldwide each year.1 While much attention is rightfully given to the diagnosis and treatment of active tuberculosis infection, the long-term consequences of tuberculosis extend beyond the initial infection. Post-tuberculosis lung disease (PTLD) represents a significant challenge in the management of tuberculosis patients, with potentially debilitating effects on respiratory function and overall quality of life.2 In this editorial, the complexities of PTLD, including its pathophysiology, clinical manifestations, diagnostic challenges, and implications for global health, are discussed.

PTLD arises as a consequence of the pulmonary damage caused by an active tuberculosis infection. The immune response to tuberculosis bacilli leads to inflammation and tissue destruction within the lungs, resulting in scarring, fibrosis, and bronchiectasis. These structural changes impair lung function and ventilation, predisposing individuals to chronic respiratory symptoms and complications.3

The clinical presentation of PTLD can vary widely, ranging from mild respiratory symptoms to severe respiratory failure. Common manifestations include chronic cough, dyspnea, hemoptysis, and recurrent respiratory infections. Additionally, PTLD may lead to progressive airflow limitation, resembling chronic obstructive pulmonary disease or restrictive lung disease due to fibrotic changes.4

Diagnosing PTLD poses several challenges, primarily due to its heterogeneous presentation and overlap with other respiratory conditions. Pulmonary function tests often reveal obstructive or restrictive patterns, reflecting the underlying lung damage.5 Radiological imaging, such as chest X-rays or computed tomography scans, may demonstrate features of bronchiectasis, cavitation, fibrosis, or nodular opacities, but these findings are not specific to PTLD.6 Furthermore, microbiological confirmation of tuberculosis may be challenging in individuals with inactive or resolved tuberculosis infection.

PTLD represents a significant burden on global health systems, particularly in regions with high tuberculosis prevalence. The long-term sequelae of tuberculosis infection contribute to increased morbidity and mortality rates, further straining already resource-limited healthcare infrastructures.7 Additionally, PTLD disproportionately affects socioeconomically disadvantaged populations, exacerbating existing health disparities.4

Managing PTLD requires a comprehensive approach aimed at alleviating symptoms, preserving lung function, and preventing disease progression. Pharmacological interventions, such as inhaled bronchodilators, corticosteroids, and mucolytics, may help improve respiratory symptoms and reduce exacerbations.4 Pulmonary rehabilitation programs, including breathing exercises and physical therapy, can enhance exercise tolerance and quality of life.8 Surgical interventions, such as lung volume reduction surgery or lung transplantation, may be considered in select cases with advanced disease.4

Preventing PTLD begins with effective tuberculosis control measures, including early detection, prompt treatment initiation, and contact tracing to prevent transmission.9 Additionally, efforts to improve tuberculosis treatment adherence and address social determinants of health, such as poverty and malnutrition, are essential for reducing the incidence of PTLD.4 Vaccination against common respiratory pathogens, such as influenza and pneumococcus, can help reduce the risk of respiratory infections and complications in tuberculosis survivors.10

Conclusions

Post-tuberculosis lung disease represents a complex and often overlooked consequence of tuberculosis infection, with profound implications for global health. Understanding the pathophysiology, clinical manifestations, and diagnostic challenges of PTLD is crucial for improving patient outcomes and reducing disease burden. Moving forward, concerted efforts are needed to raise awareness, enhance diagnostic capabilities, and develop effective management strategies for PTLD, ultimately improving the long-term health outcomes of tuberculosis survivors worldwide.

Source of Funding

None.

Conflicts of Interest

None declared.

Acknowledgements

None.

References

1 

S Yadav G Rawal M Jeyaraman India's decision to deny an extension of patent for bedaquiline: a public health imperativeCureus202315114954210.7759/cureus.49542

2 

E Nuwagira JB Baluku DB Meya LL Philpotts MJ Siedner F Bajunirwe clinical features and outcomes of post-tuberculosis lung disease in sub-Saharan Africa: a protocol for a systematic review and meta-analysisBMJ Open2022128e06226010.1136/bmjopen-2022-062260

3 

G Cupido G Günther Post tuberculosis lung disease and tuberculosis sequelae: A narrative reviewIndian J Tuberc20247116472

4 

R Nightingale F Carlin J Meghji D Evans MM van der Zalm MG Anthony Post-TB health and wellbeingInt J Tuberc Lung Dis202327424883

5 

M I Chushkin O N Ots Impaired pulmonary function after treatment for tuberculosis: the end of the disease?J Bras Pneumol20174313843

6 

W Seo HW Kim JS Kim J Min Long term management of people with post-tuberculosis lung diseaseKorean J Intern Med2024391724

7 

E Maleche-Obimbo M A Odhiambo L Njeri M Mburu W Jaoko F Were Magnitude and factors associated with post-tuberculosis lung disease in low- and middle-income countries: A systematic review and meta-analysisPLOS Glob Public Health202221280510.1371/journal.pgph.0000805

8 

M Ando A Mori H Esaki T Shiraki H Uemura M Okazawa The effect of pulmonary rehabilitation in patients with post-tuberculosis lung disorderChest20031236198895

9 

Y Ma X P Ye X Y Fu G H Wu Post-tuberculosis lung disease: a neglected diseaseZhonghua Jie He He Hu Xi Za Zhi202245109559

10 

MJ Nasiri DR Silva F Rommasi MM Zahmatkesh Z Tajabadi F Khelghati Vaccination in post-tuberculosis lung disease management: A review of the evidencePulmonology2023S2531-0437(23)00129-010.1016/j.pulmoe.2023.07.002



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 25-03-2024

Accepted : 12-04-2024


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijirm.2024.001


Article Metrics






Article Access statistics

Viewed: 594

PDF Downloaded: 330



Medical Abbreviation List